Taureau
Administrator
Also known as endurobol, cardarine, and GSK-516; GW501516 is a Peroxisome proliferator-activated receptor beta/delta agonist, or a PPAR drug for short. In spite of the fact that it is often associated to SARMS (selective androgen receptor modulators), it is actually not a SARM (it's not even hormonal). However, it is popularly stacked and sold along with SARMS, so many in the fitness community will think that it is also a SARM.
History
GW501516 was discovered in a dual partnership between GSK and Ligand Pharma, which began in the early 1990's. In fact, there was a publication in the National Academy of Sciences in 2001, where the development of the drug was outlined. Phase 1 trials began in 2000, and by 2007 GW had completed phase 2 clinical studies pertaining to obesity related problems like diabetes, and cardiovascular disease. Unfortunately, it was discontinued from medical use for reasons unknown, but has since become extremely popular in the fitness community.
Interestingly, peer reviewed scientific journals blew the lid off the drug soon after, and such important media publishers as the New York Times popularized its benefits. As a result, ahead of the 2008 Olympics, athletes started getting a hold of the drug to the dismay of doping agencies, who did not have testing protocols on it yet. It was not until the next year that urine tests were developed to prevent athletic doping with the use of Cardarine (GW).
How it Works
In terms of medical benefits, Cardarine lowers triglycerides and blood sugar. Additionally, it also helps with cholesterol levels, and improves overall heart health. As you may have noticed, these are all issues related to its main objective – reducing obesity and increasing fat loss. If that were not enough, by activating the same pathways that are triggered when we exercise, GW501516 will give a drastic boost to endurance as well.
Scientific studies made with GW
Rat studies showed that Cardarine (GW) binded to PPAR leads to an activation of the coactivator PGC-1a, which is a protein encoded with a PPARGC1A gene. The next step is the upregulation of the proteins involved in energy usage. Rats demonstrated a pronounced protection against type 2 diabetes, and a blockage of obesity from poor diet. The icing on the cake was the increase in fatty acid metabolism in skeletal muscles. Moreover, further animal studies showed a rise in good cholesterol.
History
GW501516 was discovered in a dual partnership between GSK and Ligand Pharma, which began in the early 1990's. In fact, there was a publication in the National Academy of Sciences in 2001, where the development of the drug was outlined. Phase 1 trials began in 2000, and by 2007 GW had completed phase 2 clinical studies pertaining to obesity related problems like diabetes, and cardiovascular disease. Unfortunately, it was discontinued from medical use for reasons unknown, but has since become extremely popular in the fitness community.
Interestingly, peer reviewed scientific journals blew the lid off the drug soon after, and such important media publishers as the New York Times popularized its benefits. As a result, ahead of the 2008 Olympics, athletes started getting a hold of the drug to the dismay of doping agencies, who did not have testing protocols on it yet. It was not until the next year that urine tests were developed to prevent athletic doping with the use of Cardarine (GW).
How it Works
In terms of medical benefits, Cardarine lowers triglycerides and blood sugar. Additionally, it also helps with cholesterol levels, and improves overall heart health. As you may have noticed, these are all issues related to its main objective – reducing obesity and increasing fat loss. If that were not enough, by activating the same pathways that are triggered when we exercise, GW501516 will give a drastic boost to endurance as well.
Scientific studies made with GW
Rat studies showed that Cardarine (GW) binded to PPAR leads to an activation of the coactivator PGC-1a, which is a protein encoded with a PPARGC1A gene. The next step is the upregulation of the proteins involved in energy usage. Rats demonstrated a pronounced protection against type 2 diabetes, and a blockage of obesity from poor diet. The icing on the cake was the increase in fatty acid metabolism in skeletal muscles. Moreover, further animal studies showed a rise in good cholesterol.